Change in Blood Pressure, Weight, and Other Cardiovascular Disease Risk Factors After Switch From Protease Inhibitors to Dolutegravir: Post hoc Analysis of the 48-week Randomised Second-line Switch to Dolutegravir Trial. [PDF]
Ombajo LA+7 more
europepmc +1 more source
Effect of weight gain on blood pressure in Ugandan persons with HIV on dolutegravir/lamivudine/ tenofovir disoproxil fumarate over 48 weeks. [PDF]
Amutuhaire W+8 more
europepmc +1 more source
Associations Between Antiretroviral Regimen and Changes in Blood Pressure: Results From the D2EFT Study. [PDF]
Nyein PP+11 more
europepmc +1 more source
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia. [PDF]
Calza L+6 more
europepmc +1 more source
Polatuzumab Vedotin, zanubrutinib and rituximab (Pola-ZR) achieved rapid and deep response in untreated frail and elderly DLBCL. [PDF]
Ren Y+10 more
europepmc +1 more source
Super-resolution imaging with a cucurbituril-encapsulated fluorophore.
Briant L, Maillard J, Fürstenberg A.
europepmc +1 more source
Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV. [PDF]
Wang Z+12 more
europepmc +1 more source